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INTRODUCTION

Individuals have limited monopolies in the areas of patents,'
copyrights, 2 and trademarks. 3 One limitation of these monopolies is
known as the first sale doctrine. The first sale doctrine allows a party to
use or sell legally obtained goods that are protected by intellectual
property without violating the intellectual property owner's right to the
monopoly.4
In patent law, the first sale doctrine is also called "patent
exhaustion." Although the first sale doctrine in patent law has not been
codified, a parallel concept in copyright has been codified. The
codification states that once a copy of the copyrighted material has been
lawfully sold or its ownership otherwise lawfully transferred, the buyer
of that copy and subsequent owners are free to dispose of it as they
wish, where the "first sale" has "exhausted" the copyright owner's
exclusive distribution right.5 Similarly, the doctrine of patent exhaustion
"provides that the initial authorized sale of a patented item terminates
1. See 35 U.S.C. § 154 (2012). A patent owner has "the right to exclude others from
making, using, offering for sale, or selling the invention throughout the United States." Id. §
154(a)(1).
2. See 17 U.S.C. §§ 106, 109 (2012). The copyright owner has the exclusive right to
authorize and to reproduce, prepare derivatives, distribute copies, and to publicly perform and
display his copyrighted material. Id. § 106(l)-(6).
3. See 15 U.S.C. §§ 1114, 1125 (2012). Any person using a mark in a manner that "is
likely to cause confusion" may be liable in a civil action brought by the mark holder. Id. §
II 14(l)(a).
4. See, e.g., Adams v. Burke, 84 U.S. 453, 456-57 (1873) (refusing to find patent
infringement when the purchaser of a patented coffin lid used it outside the territory in which
the manufacturer was licensed); Bobbs-Merrill Co. v. Straus, 210 U.S. 339, 350-51 (1908)
(finding that copyright owners had no rights to further control what happened to books after
they sold them); Champion Spark Plug Co. v. Sanders, 331 U.S. 125, 131-32 (1947) (allowing a
second-hand spark plug dealer to use original Champion trademark on product packaging
because the packaging explicitly stated that the spark plugs were used or second-hand).
5. See 17 U.S.C. § 109(a) ("[T]he owner of a particular copy or phonorecord lawfully
made under this title, or any person authorized by such owner, is entitled, without the authority
of the copyright owner, to sell or otherwise dispose of the possession of that copy or
phonorecord."); see also Kirtsaeng v. John Wiley & Sons, Inc., 133 S. Ct. 1351, 1355-56 (2013)
(holding that the first sale doctrine applies to copies of a copyrighted work lawfully made
abroad).

2013]

SELF-REPLICA TING TECHNOLOGIES: DO THEY EXHA UST PA TENT RIGHTS?

199

all patent rights to that item."6 However, it has not been entirely clear
what constitutes an authorized sale in order for patent exhaustion to
apply.7
This issue becomes more complicated when it involves selfreplicating technologies because these technologies can produce more
patented articles. One such example is seed. Seeds grow and create
more seeds. Even if patent exhaustion applies to the sale of firstgeneration seeds, the patent owner may still retain control under the
patent laws over the second-generation seeds. 8
For cases involving seeds, the Federal Circuit has declined to apply
patent exhaustion after initial sales on the grounds of the conditional
sale doctrine and the making of new infringing articles. Monsanto was
able to enforce its rights under the patent laws to control and limit the
use of the patented seeds.' 0 Since Quanta Computer, Inc. v. LG
Electronics, Inc.," however, many have questioned the continued
viability of the conditional sale doctrine; and, if patent exhaustion now
applies to the patented seeds, whether it will exhaust Monsanto's
remedy under patent law.12 The Supreme Court answered that question
in Bowman v. Monsanto Co. 13 by holding that patent exhaustion does
not apply to the seeds because planting and harvesting seeds constitutes
making new articles.14 The decision will likely have implications for
other self-replicating technologies, especially those within the
biotechnology industries.
This Article proceeds as follows. Part I provides relevant
background on the law of patent exhaustion. Part II details the restricted
sale at the Supreme Court and the conditional sale at the Federal Circuit.
6. Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617, 625 (2008).
7. Jonathan Werner, Note, Filling in the Gaps: The Limits of the Patent Exhaustion
Doctrine in Light of the Supreme Court's Inability to Find Closure in Quanta, 15 J. TECH. L. &
POL'Y 275, 286 (2010).

8. See Bowman v. Monsanto Co., 133 S. Ct. 1761, 1769 (2013) (holding that the patent
exhaustion doctrine did not permit a farmer who purchased patented seeds to reproduce the
seeds without the patent holders permission).
9. Monsanto Co. v. Bowman, 657 F.3d 1341, 1347-48 (Fed. Cir. 2011), aff'd, 133 S. Ct.
1761 (2013).
10. See Monsanto Co. v. McFarling, 302 F.3d 1291 (Fed. Cir. 2002); Monsanto Co. v.
Scruggs, 459 F.3d 1328 (Fed. Cir. 2006); Monsanto Co. v. Bowman, 657 F.3d 1341 (Fed. Cir.
2011).
11. 553 U.S. 617 (2008).
12. See Herbert Hovenkamp, Post-Sale Restraints and Competitive Harm: The First Sale
Doctrine in Perspective, 66 N.Y.U. ANN. SURv. AM. L. 487, 502 (2011); Thomas G. Hungar,
ObservationsRegarding the Supreme Court's Decision in Quanta Computer, Inc. v. LG Elecs.,
Inc., 49 IDEA 517, 533 (2009); Static Control Components, Inc. v. Lexmark Int'l, Inc., 615 F.
Supp. 2d 575, 585-86 (E.D. Ky. 2009).
13. 133 S. Ct. 1761 (2013).
14. Id. at 1765-69.
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Part III discusses various self-replicating technologies and explains that
not all self-replicating technologies are the same. Some are capable of
easily reproducing an unlimited number of copies, while others may
require a significant amount of resource and human intervention to
replicate. Additionally, under certain circumstances, an article can be
induced to make a similar, but not identical copy. An example of this is
a DNA segment with mutations. Part IV details the seed cases at the
Federal Circuit. Part V reviews the Supreme Court's decision in
Bowman v. Monsanto and discusses the potential impact of the ruling.
Part VI discusses issues not decided in the Court's opinion about
whether the sale was authorized and the situation of inadvertent
infringement. This Article concludes that making new copies of seeds
falls outside the doctrine of patent exhaustion, which provides guidance
for other self-replicating technologies, such as in the field of
biotechnology.
I. THE PATENT EXHAUSTION DOCTRINE

A patent gives its holder the right to exclude others from making,
using, offering for sale, or selling the invention.' 5 However, this right of
a patent holder conflicts with the right of a purchaser to control the
downstream sale and use of patented goods.' 6 To protect public interest,
the patent owner's exclusive rights are limited in scope. The doctrine
of patent exhaustion, or the first sale doctrine, limits the extent to which
patent holders can control a patented product after an authorized sale.' 8
Under this doctrine, once an authorized sale of a patented article occurs,
the patent owner's exclusive rights to control the use and sale of that
article are exhausted.19 The patent owner may not control the
downstream consumers regarding the use and disposal of the article by
bringing a patent infringement suit; and thus, the purchaser is free to use
15. See 35 U.S.C. § 154(a)(1) (201 2 ).
16. Amelia Smith Rinehart, ContractingPatents: A Modern PatentExhaustion Doctrine,
23 HARv. J.L. & TECH. 483, 484 (2010).
17. See United States v. Masonite Corp., 316 U.S. 265, 280 (1942) ("Since patents are
privileges restrictive of a free economy, the rights which Congress has attached to them must be
strictly construed so as not to derogate from the general law beyond the necessary requirements
of the patent statute.").
18. See, e.g., Adams v. Burke, 84 U.S. 453, 456 (1873) ("That so far as the use of it was
concerned, the patentee had received his consideration, and it was no longer within the
monopoly of the patent."); see also 35 U.S.C. § 271(d) ("No patent owner otherwise entitled to
relief for infringement or contributory infringement of a patent shall be denied relief or deemed
guilty of misuse or illegal extension of the patent right .... .").
19. See generally Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617, 625-38
(2008).
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or resell that article without further restraint from patent law.2 0 Absent
patent exhaustion, a buyer would hesitate to purchase a product from
the patent owner because resale of the product could infringe the patent
owner's rights.21
The use or sale of a patented article may constitute infringement if
carried out "without authorit ."2 2 Because patent exhaustion applies to
"the initial authorized sale," 2 procedurally, it operates as an affirmative
defense, shielding authorized purchasers from patent infringement. 24
The first sale doctrine originated from the common law policy
against restraints on alienation. 2 5 The origins of patent exhaustion
generally are traced back to the 1853 case of Bloomer v. McQuewan,26
although the Court cited in that opinion to an earlier case, Wilson v.
Rousseau.27 In Bloomer, the defendant had purchased patent rights to
construct and sell planing machines that were used for smoothing or
shaping wood. 28 The Court established that a first sale by the patent
owner exhausted the patent owner's right to sue a purchaser for
infringement, and held that the defendant was entitled to the continuous
use of the machines embodying the patent even after the extension of

20. Id.
21. See John W. Schlicher, The New PatentExhaustion Doctrineof Quanta v. LG: What
it Meansfor Patent Owners, Licensees, and Product Customers, 90 J. PAT. & TRADEMARK OFF.
Soc'Y 758, 768 (2008).
If there were no implied license or exhaustion doctrines, patent owners would
always be forced to grant licenses to people who purchase products and need a
license to use them. No one would buy patented products ... without assurance
from the seller that use or resale of that product would not infringe a patent the
seller owned.
Id.
22. 35 U.S.C. §§ 271(a), (f), (g). The patent exhaustion doctrine does not apply to sales
outside of the United States. See Fuji Photo Film Co. v. Jazz Photo Corp., 394 F.3d 1368, 1376
(Fed. Cir. 2005). In Fuji Photo Film Co. v. Jazz Photo Corp., the Federal Circuit confirmed that
"first sales under the exhaustion doctrine [are limited] to those occurring within the United
States." Id. However, in Kirtsaeng v. John Wiley & Sons, Inc., the Supreme Court held that "the
'first sale' doctrine applies to copies of a copyrighted work lawfully made abroad." Kirtsaeng v.
John Wiley & Sons, Inc., 133 S. Ct. 1351, 1355-56 (2013).
23. Quanta, 553 U.S. at 625.
24. See PNY Techs., Inc. v. SanDisk Corp., No. C-11-04689 YGR, 2012 WL 1380271, at
*5 (N.D. Cal. Apr. 20, 2012).
25. Hovenkamp, supra note 12, at 493; see Wilson v. Rousseau, 45 U.S. 646, 674 (1864).
26. 55 U.S. 539, 540 (1853).
27. See Quanta, 553 U.S. at 625 ("This Court first applied the doctrine in 19th-century
cases addressing patent extensions on the Woodworth planing machine."); Wilson, 45 U.S. at
647.
28. Bloomer, 55 U.S. at 547.
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the patent term.29 The Court explained that the "machine becomes his
private, individual property, not protected by the laws of the United
States," which suggests that the Court's motivation for patent
exhaustion comes from an appreciation of property rights. 3 0
Shortly thereafter, in 1873, the Court further clarified the first sale
doctrine in Adams v. Burke.3 1 Describing the application of patent
exhaustion, the Court stated that "when the patentee, or the person
having his rights, sells a machine or instrument whose sole value is in
its use, he receives the consideration for its use and he parts with the
right to restrict that use." 32 Thus, the patent exhaustion doctrine is also
based on the idea that the patent owner should be only fairly
compensated for having disclosed the invention from the first
authorized sale. 33 Similarly, in United States v. Univis Lens Co.,34 the
Court articulated this policy against double dipping as,
[T]he purpose of the patent law is fulfilled with respect to any
particular article when the patentee has received his reward for
the use of his invention by the sale of the article, and . . . the

patent law affords no basis for restraining the use and enjoyment
of the thing sold.3 5
In Keeler v. StandardFolding-Bed Co.,36 the Court reconsidered the
doctrine of patent exhaustion and raised the question of applying
contract law to remedy a patent owner.3 7 The Court reiterated the
reasonable compensation and property right concepts that patent
29.
30.

Id. at 549.
Id. at 550, 553.
For it can hardly be maintained that Congress could lawfully deprive a citizen
of the use of his property after he had purchased the absolute and unlimited
right from the inventor, and when that property was no longer held under the
protection and control of the General Government, but under the protection of
the State, and on that account subject to State taxation.

Id; see Andrew T. Dufresne, Note, The Exhaustion Doctrine Revived? Assessing the Scope and
Possible Effects of the Supreme Court's Quanta Decision, 24 BERKELEY TECH. L.J. 11, 13
(2009); see also Werner, supra note 7, at 277.
31. 84 U.S. 453, 457 (1873) (noting that when an invention is "lawfully made and sold,
there is no restriction on [its] use to be implied for the benefit of the patentee or his assignees or
licensees").
32. Id. at 456.
33. See Bloomer v. Millinger, 68 U.S. 340, 350 (1863) ("[Patentees] are entitled to but
one royalty for a patented machine.. ...
34. 316 U.S. 241 (1942).
35. Id. at 251.
36. 157 U.S. 659 (1895).
37. Id. at 666.
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exhaustion was based on, providing that the patent owner should be
paid only once and, consequently, the buyer of a patented article
possesses absolute property right of them, unrestricted in time or
space.38 Although the Court did not express an opinion about whether a
license can be used to protect the patent owner, the Court stated that
such a question would arise under contract law, not patent law. 39
Later, the Supreme Court applied patent exhaustion based on the
policy of avoiding stifling market competition by finding that restraints,
such as tying arrangements and price fixing, were not enforceable in
patent infringement actions.40 In Motion Picture Patents Co. v.
Universal Film Manufacturing Co.,4 1 the Court condemned a tying
arrangement under which the patent owner limited the use of a projector
to the showing of the patent owner's own films. 42 Additionally, in
Univis, a patent owner sold lens blanks subject to a price restriction that
the Supreme Court ultimately found violated the first sale doctrine.4 3
While one objective of the patent laws is "to stimulate the efforts of
genius" by providing a reasonable reward and exclusive rights for a
designated amount of time, "the primary purpose . . . is not the creation

of private fortunes for the owners of patents.

4

II. AUTHORIZED SALE: TENSION BETWEEN THE SUPREME
COURT AND THE FEDERAL CIRCUIT

An authorized sale arises in different forms. Most typically, the sale
from a patent owner to a consumer without any restrictions imposed is
38.

Id.
[T]he payment of a royalty once, or, what is the same thing, the purchase of the
article from one authorized by the patentee to sell it, emancipates such article
from any further subjection to the patent throughout the entire life of the patent.
... [O]ne who buys patented articles of manufacture from one authorized to
sell them becomes possessed of an absolute property in such articles,
unrestricted in time or place.

Id
39. Id. ("Whether a patentee may protect himself and his assignees by special contracts
brought home to the purchasers is . ... a question [that] would arise as a question of contract,
and not as one under the inherent meaning and effect of the patent laws.").
40. See Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U.S. 502, 519 (1917)
(tying arrangements); see also Univis, 316 U.S. at 254 (price fixing).
41. 243 U.S. 502 (1917).
42. Id at 518-19.
43. See Univis, 316 U.S. at 251-54.
44. Motion PicturePatents, 243 U.S. at 511 (quoting Pennock v. Dialogue, 27 U.S. 1, 19
(1829)).
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clearly an authorized sale.4 5 In addition, an authorized sale may arise
from transactions between a licensee of the latent owner and a
purchaser, 46 or from a patent owner to a licensee. The Federal Circuit
explicitly stated that "this longstanding principle [of patent exhaustion]
applies similarly to a sale of a patented product manufactured by a
licensee acting within the scope of its license."48
Because an authorized, unconditional sale prevents a patent owner
from enforcing his patent rights as to the goods sold,49 patent owners
began placing conditions onto goods sold attempting to contract around
the patent exhaustion doctrine.50 However, courts have not provided
firm principles about restrictions that permissibly avoid patent
exhaustion. After Quanta, post-sale restrictions appear to prevent
parties from contracting around patent exhaustion because the Supreme
Court articulated that "[t]he authorized sale of an article that
substantially embodies a patent exhausts the patent holder's rights and
prevents the patent holder from invoking patent law to control postsale
use of the article." 5 '
According to the Federal Circuit, the patent exhaustion doctrine
"does not apply to an expressly conditional sale or license." 52 This
restriction has led to discussions about whether Monsanto's practice
constitutes a license or a sale, or both a license and a sale. 53 The
45. See Rinehart, supra note 16, at 492 ("When the patent owner sells the good to another
without restricting the sale, the patent owner's rights to exclude resale and future use of the
good are exhausted as to that good.").
46. See, e.g., Adams v. Burke, 84 U.S. 453, 457 (1873); Bauer & Cie v. O'Donnell, 229
U.S. 1, 9 (1913); Ethyl Gasoline Corp. v. United States, 309 U.S. 436, 447 (1940); Quanta
Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617, 623-24 (2008).
47. See e.g., Univis, 316 U.S. at 243-44.
48. Intel Corp. v. ULSI Sys. Tech., Inc., 995 F.2d 1566, 1568 (Fed. Cir. 1993) (citing
Unidisco, Inc. v. Schattner, 824 F.2d 965, 968 (Fed. Cir. 1987)).
49. See, e.g., Mitchell v. Hawley, 83 U.S. 544, 547 (1872).
[A] patentee, when he has himself constructed a machine and sold it without
any conditions, or authorized another to construct, sell, and deliver it, or to
construct and use and operate it, without any conditions, and the consideration
has been paid to him for the thing patented, the rule is well established that the
patentee must be understood to have parted to that extent with all his exclusive
right, and that he ceases to have any interest whatever in the patented machine
so sold and delivered or authorized to be constructed and operated.
Id.
50. See, e.g., Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U.S. 502, 506
(1917).
51. Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617, 638 (2008).
52. B. Braun Med., Inc. v. Abbott Labs., 124 F.3d 1419, 1426 (Fed. Cir. 1997).
53. See generally Douglas Fretty, Note, Both a License and a Sale: How to Reconcile
Self-Replicating Technology with Patent Exhaustion, 5 J. Bus. ENTREPRENEURSHIP & L. 1, 4
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designation of Monsanto's practice as a license or a sale matters
because a pure license with restrictions enables a patent owner to
contract around patent exhaustion while a pure sale triggers patent
exhaustion. 54 It has also been observed that when restrictions fall
outside of the scope of patent rights, contracting around patent
exhaustion can be effective; and further, "license restrictions that are not
within the scope of patent rights are considered patent misuse and not
allowed."ss For example, when restrictions relate to price fixing and
tying arrangements, the Court has held that patent exhaustion applies.
To encourage innovation, "federal law has struck a balance between
incentives for inventors and the public's right to a competitive
economy."5 From the Supreme Court's recent review of a number of
patent cases, the Court has consistently found against patent owners and
has been cutting back on the strength of patent rights. 58 In Quanta, the
Supreme Court's latest decision regarding patent exhaustion, the Court
reversed the Federal Circuit, finding that method patents are
exhaustible, and thus, denying LGE's assertion of its patent rights
against companies down the line of commerce. 59 While the Federal
Circuit's conditional sale doctrine provides broad protection to the
patent owner by allowing post-sale restrictions to prevent exhaustion of
the patent owner's rights, the Supreme Court appears to reject the
conditional sale doctrine in Quanta by providing downstream
purchasers, not patent owners, with more protection under the patent

laws. 60
The following Part II.A analyzes the decisions of the Supreme Court
as to restrictions that did and did not result in authorized sales.
Subsequently, Part II.B evaluates the conditional sale doctrine at the
Federal Circuit.
(2011).
54. See Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700, 706 (Fed. Cir. 1992).
55. Yina Dong, Note, A Patent Exhaustion Exposition: Situating Quanta v. LGE in the
Context ofSupreme CourtJurisprudence,2010 STAN. TECH. L. REv. N2, 1, 23 (2010).
56. Bauer & Cie v. O'Donnell, 229 U.S. 1, 9,18 (1913).
57. Martin J. Adelman, Secrecy and Patenting: Some Proposals for Resolving the
Conflict, 1 APLA Q.J. 295, 299 (1973).
58. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1294
(2012) (finding that correlations between blood test results and patient health is not eligible for a
patent because the correlations incorporate laws of nature); Microsoft Corp. v. AT&T Corp.,
550 U.S. 427, 455 (2007) (limiting a patent holder's ability to recover damages for infringement
in foreign countries); KSR Int'l Co. v. Teleflex, Inc., 550 U.S. 398, 404 (2007) (making it easier
to invalidate a patent for obviousness); eBay, Inc. v. MercExchange, L.L.C., 547 U.S. 388, 394
(2006) (holding that the granting of an injunction in a patent case must be determined in
accordance with the same standards as all other cases, "with traditional principals of equity").
59. Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617, 629-30 (2008).
60. See Jeremy N. Sheff, Self-Replicating Technologies, 16 STAN. TECH. L. REv. 229, 234
(2013).
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A. Restricted Sale: The Supreme Court Precedents6 1
The Supreme Court has not provided a clear answer as to whether
the patent exhaustion doctrine prohibits all post-sale patent
enforcement, and thus prevents the parties from contracting around the
exhaustion doctrine. 62 The Court developed a line of cases drawing a
distinction between authorized restricted sales and unauthorized
restricted sales. Both Mitchell v. Hawle63 and General Talking Pictures
Corp. v. Western Electric Co. 64 involved two restrictions that resulted in
unauthorized sales where patent exhaustion did not apply. 65 In Mitchell,
the Court recognized that a patent owner might grant a manufacturer a
license to make and sell a patented article limited to a fixed span of
time.66 In General Talking Pictures, the Court also approved of field-ofuse restrictions, which limit use of a patented invention to a specified
application of market; therefore, the patent owners could grant restricted
licenses to manufacturers and enforce the restrictions against the
licensee's purchases through infringement suits.67
Moreover, the facts of Mitchell contrast those of Bloomer. In
Mitchell, the conditional license-an express provision restricting the
use beyond the original term-prevented exhaustion. 68 In Bloomer, the
unconditional license-no provision restricting the use beyond the
original patent term-gave rise to exhaustion.6 9
The Court has not been consistent about whether notice is required
to enforce the restrictions. The Court hinted that notice restrictions may
be enforceable as to downstream purchasers in General Talking
61. A restricted sale is any sale that imposes conditions or requirements upon the
purchaser. See Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700, 706 (Fed. Cir. 1992). A
restricted sale may be an authorized sale or an unauthorized sale. See Quanta, 553 U.S. at 621.
62. Vincent Chiappetta, Patent Exhaustion: What's It Good For?, 51 SANTA CLARA L.
REV. 1087, 1098 (2011).

63. 83 U.S. 544 (1872).
64. 304 U.S. 175 (1937).
65. Mitchell, 83 U.S. at 548; Gen. Talking Pictures,304 U.S. at 181-82.
66. See Mitchell, 83 U.S. at 549-50. The patentee granted a license to make, use, and
license to others his patented machine during, but explicitly not beyond, the original patent term.
Id. Subsequently, the patentee assigned his rights under an extended term to Mitchell, who sued
the first licensee for infringement due to his continued use of the machines during the extended
term. Id.
67. See Gen. Talking Pictures, 304 U.S. at 180-81. The patent owner granted a license to
make and sell patented amplifiers, but only for private and home use. Id at 179-80.
68. See Mitchell, 83 U.S. at 549. The licensee had the right to make and use, and to
sublicense the right to make and use patented machines for making felt hats in Massachusetts
and New Hampshire, with an additional provision that stated "the licensee 'shall not, in any
way, or form, dispose of sell, or grant, any license to use the said machines beyond the
expiration' of the original term." Id.
69. See Bloomer v. McQuewan, 55 U.S. 539, 541-42 (1852).
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Pictures.70 In General Talking Pictures,the sale from the licensee to the
purchaser was not authorized because the licensee knowingly violated
the use restriction when it sold patented amplifiers to a different field of
use, and what was not authorized to sell cannot be conveyed.
However, in Mitchell, notice was not required, and even an innocent
purchaser who did not know of the restriction could still be limited. 72
Similarly, in Quanta, the first purchaser of the patented product had
signed an agreement with the patent owner promising to give notice to
its own downstream purchasers about the restriction on use of the
patented product with non-Intel parts. Notwithstanding the actual
notice to the downstream purchaser, the Court applied the first sale
doctrine and refused to enforce the restraint. 74 The Court found the
notice requirement ineffective partly because the patent owner did not
allege that the licensees had breached the agreement and the notice
provision was in an agreement separate from the license agreement.75
When restricted sales are authorized, patent exhaustion applies and a
patent owner cannot sue the purchaser for patent infringement. 76
Despite the possibility of contracting around patent exhaustion, most
Supreme Court cases regarding patent exhaustion follow a pattern, and
traditional rule, that when a patent-embodying good passes from a
licensee or manufacturer to a user, it cuts off the patent owner's interest
in the good under patent law.7 7
For the purpose of patent exhaustion, the Supreme Court has
declined to recognize territorial restrictions on the right to use when
purchased lawfully and transported outside the territorial rights of the
patent owner. 78 In one of the earliest patent exhaustion cases, Adams v.
Burke, the licensee had the right to make, sell, and use patented coffin-

70. See Gen. Talking Pictures, 304 U.S. at 180.
71. Id. ("The petitioner, when purchasing from the Transformer Company for that use,
had actual knowledge that the latter had no license to make such a sale.").
72. See Mitchell, 83 U.S. at 550.
Persons, therefore, who buy goods from one not the owner, and who does not
lawfully represent the owner, however innocent they may be, obtain no
property whatever in the goods, as no one can convey in such a case any better
title than he owns, unless the sale is made in market overt, or under
circumstances which show that the seller lawfully represented the owner.
Id.
73.
74.
75.
76.
77.
78.

Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617, 623-24 (2008).
Id. at 637-38.
Id. at 619.
Id. at 621.
See id. at 618.
See, e.g., Adams v. Burke, 84 U.S. 453 (1873).

JOURNAL OF TECHNOLOGYLAW & POLICY

208

[Vol. I18

lids within a ten-mile radius around Boston. 79 Despite this geographic
restriction, a customer bought a coffin-lid in Boston and used it outside
of the ten-mile radius.80 Similarly, in Hobbie v. Jennison,8 1 an assignee
made and sold pipes in Michigan, knowing that they were to be used in
Connecticut, a territory that the assignee did not own the rights for. 82
Notwithstanding the restrictions, the Supreme Court found authorized
sales and applied patent exhaustion in both cases. 83
When the restrictions are related to antitrust arrangements, such as
tying arrangements or price fixing, the sales are authorized and patent
exhaustion applies. 84 The Supreme Court briefly acknowledged a postsale restriction in Henry v. A.B. Dick Co.,85 but distinguished Henry in
1913 in Bauer & Cie. v. O'Donnell,86 and finally overruled it in 1917 in
Motion PicturesPatents.8 7 In Henry, the Court explicitly distinguished
between unconditional and conditional sales and expressly held that
exhaustion did not preclude post-sale patent law enforcement of
violations of restrictions imposed in the latter kind of transaction.8 In
Bauer, the Court held that the first sale doctrine precluded a firm from
79.
80.
81.
82.
83.

Id at 456.
See id.
149 U.S. 355.
See id at 356.
See Adams, 84 U.S. at 456.
[W]hen the patentee, or the person having his rights, sells a machine or
instrument whose sole value is in its use, he receives the consideration for its
use and he parts with the right to restrict that use. The article, in the language of
the court, passes without the limit of the monopoly.

Id; Hobbie, 149 U.S. at 363 ("[T]he sale was a complete one at Bay City [Michigan]; and []
neither the actual use of the pipes in Connecticut, or a knowledge on the part of the defendant
that they were intended to be used there, can make him liable.").
84. See Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U.S. 502, 517
(1917).
85. 224 U.S. 1,25 (1912).
It is plain from the power of the patentee to subdivide his exclusive right of use
that when he makes and sells a patented device that the extent of the license to
use which is carried by the sale must depend upon whether any restriction was
placed upon the use and brought home to the person acquiring the article.
Id. The machine sold by A.B. Dick Company included a license restriction that required that the
machine be used only with supplies made by A.B. Dick Company, such as the stencil paper and
ink. Id. at 11.
86. 229 U.S. 1 (1913).
87. Id. at 16; Motion PicturePatents,243 U.S. at 518.
88. See Henry, 224 U.S. at 24-25 ("[Ihf the right of use be confined by specific
restriction, the use not permitted is necessarily reserved to the patentee. If that reserved control
of use of the machine be violated, the patent is thereby invaded.").
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using a patent license restriction to impose resale price maintenance on
a patented medicine.8 9
Between Henry and Motion Picture Patents, Congress passed
section 3 of the Clayton Act in 1914, which made anticompetitive ties
unlawful despite whether the tying products were patented or not. 90 In
Motion PicturePatents, the patent owner granted a license to make and
sell patented motion picture projectors, with a restriction that the
machines sold could show only films covered under a separately
licensed patent. 9 1 While the Court found support for its decision in the
Clayton Act, the analysis in Motion Picture Patents was based almost
exclusively on the first sale doctrine. 92 It is one of many opinions in
which the Court combined the first sale doctrine and antitrust concerns,
and it is widely cited as a decision encompassing both early patent
misuse as well as antitrust law. 9 3
Another case relating to price restrictions placed on patented
products is Univis, where the patent owner manufactured lens blanks
and sold them to licensees with a restriction that the licensees could not
sell the finished eyeglass lenses prepared from the lens blanks below
specified minimum resale prices.9 The Court found that the price fixing
restriction violated the first sale doctrine because an authorized sale
exhausted the patent owner's monopoly in the lenses. 95
Patent exhaustion also applies to sales of components that, when
combined with other components, practice the patented method. 96 In
both Univis and Quanta, the Court applied the patent exhaustion
doctrine to incomplete articles that have no substantial use other than to
be manufactured into a separate patented and allegedly infringing

89. See Bauer, 229 U.S. at 17. The patentee granted to the licensee its patent rights to a
drug, and the licensee then sold the drug to retailers with the requirement that the resale price
had to be more than one dollar, and stated that any use or sale in violation of this condition
constituted a patent infringement. Id. at 8-9.
90. See Clayton Act, ch. 323, § 3, 38 Stat. 730, 731 (1914) (current version at 15 U.S.C. §
14 (2012)).
91. See Motion PicturePatents, 243 U.S. at 506.
92. Id. at 517-18. The Court reasoned that it would be a "perfect instrument of favoritism
and oppression" if a patented product, upon being sold and paid for, could still be subject to
restrictions or conditions as to the product's use. Id. at 515. The Court noted that the "fair as
well as the statutory measure of [the patentee's] reward for his contribution to the public stock
of knowledge" was the funds derived from the sale of the right to the "exclusive use of the new
and useful discovery." Id. at 513.
93. Hovenkamp, supra note 12, at 501, 510.
94. See United States v. Univis Lens Co., 316 U.S. 241, 243-45 (1942).
95. Id. at 250 ("[Siale of [the patented article] exhausts the monopoly in that article and
the patentee may not thereafter, by virtue of his patent, control the use or disposition of the
article.").
96. See Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617, 632 (2008).
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article. 9 7 In Univis, the lens was capable of use only in practicing the
patent, and in Quanta, the licensed components were an essential
feature of the downstream patents and not capable of non-infringing
uses.98 When a patent owner or his licensee sells a component or
unfinished article embodying the "essential features of his patented
invention," and he intends that the purchaser complete the article
consistent with the patent, "he has sold his invention so far as it is or
may be embodied in that particular article." 99
B. ConditionalSale: The FederalCircuit Cases
In 1992, the Federal Circuit set forth its interpretation of the
conditional sale doctrine and approved the use of post-sale restrictions
in Mallinckrodt, Inc. v. Medipart, Inc. 00 The Federal Circuit enforced
the "single use only" restriction, and held that the restricted sale of the
patented device did not exhaust the patent and that violation of the
restriction was actionable as patent infringement as long as the sale
"was validly conditioned under the applicable law."' 0 The Federal
Circuit found the use restriction to be enforceable as a matter of patent
law as long as Mallinckrodt committed no antitrust or patent misuse
violations due to there being no accompanying price-fixing or forced
product tie-ins and the restriction was reasonable within the patent
granted monopoly.102 The Federal Circuit reasoned that since a patent
owner has exclusion rights, the patent owner may choose to waive only
a portion of those exclusive rights.'0 3
In arriving at is decision, the Federal Circuit relied on Supreme
Court precedents, interpreting Bloomer, Adams, Mitchell, and Keeler as
demonstrating that an unconditional sale of a patented device exhausts
97. Univis, 316 U.S. at 250-51; Quanta, 553 U.S. at 632.
98. Quanta, 553 U.S. at 632; Univis, 316 U.S. at 249.
99. Univis, 316 U.S. at 251.
100. See Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700, 701-10 (Fed. Cir. 1992).
101. Id. at 709. Mallinckrodt, the patent owner, sold its medical devices to hospitals with a
"single use only" restriction. Id. at 702. Instead of disposing of the devices after the first use,
however, the hospitals sent the devices to Medipart for sterilization and subsequently reused
them. Id.
102. Id. at 709.
If the sale of the Ultra-Vent was validly conditioned under the applicable law
such as the law governing sales and licenses, and if the restriction on reuse was
within the scope of the patent grant or otherwise justified, then violation of the
restriction may be remedied by action for patent infringement.
Id.
103.

Id. at 703 ("This right to exclude may be waived in whole or in part."); see 35 U.S.C.

§ 154 (2012).
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the patent owner's right to restrict the article's use.104 In addition, the
Federal Circuit cited Univis as an example of potential limitations on
conditions of sale where the condition violated some other law or
policy, such as patent misuse or antitrust law.' 0 5
In the following case of B. Braun Medical, Inc. v. Abbott
Laboratories,106 the Federal Circuit again held that the exhaustion
doctrine "does not apply to an expressly conditional sale or license"
because "it is reasonable to infer that the parties negotiated a price that
reflects only the value of the [] rights conferred by the patentee."' 0 7 The
Federal Circuit also emphasized that "[t]he key inquiry under the factintensive patent exhaustion doctrine is" the anticompetitive effect of the
condition. o8
The Supreme Court in Quanta did not explicitly overrule
Mallinckrodt, but many have questioned the continued viability of
Mallinckrodt since Quanta.109 It remains unclear to what extent a patent
owner can use a conditional license to impose restrictions on
downstream purchasers to avoid patent exhaustion or whether the
Quanta opinion has affirmatively rejected the view that one can contract
around the doctrine. 110 However, at least one district court has
concluded that Mallinckrodt is no longer good law after Quanta."'
Whether or not Mallinckrodtis still good law, the Federal Circuit has
since held that a restricted sale that imposes an unconditional covenant
not to sue upon the purchaser does authorize sales by the purchaser, and
thus, patent exhaustion applies." 2 The Federal Circuit noted that the
pertinent question was "not whether an agreement is framed in terms of
a 'covenant not to sue' or a 'license.' That difference is only one of

104. See Mallinckrodt, 976 F.2d at 706-08.
105. Id. at 708 ("Unless the condition violates some other law or policy (in the patent field,
notably the misuse or antitrust law), private parties retain the freedom to contract concerning
conditions of sale." (citing United States v. Univis Lens Co., 316 U.S. 241 (1942))).
106. 124 F.3d 1419 (Fed. Cir. 1997).
107. Id. at 1426.
108. Id. ("The key inquiry under this fact-intensive doctrine is whether, by imposing the
condition, the patentee has 'impermissibly broadened the physical or temporal scope of the
patent grant with anticompetitive effect."' (quoting Windsurfing Int'l, Inc. v. AMF, Inc., 782
F.2d 995, 1001 (Fed. Cir. 1986)) "[E]xpress conditions [] are contractual in nature and are
subject to antitrust, patent, contract, and any other applicable law, as well as equitable
considerations such as patent misuse.").
109. See, e.g., Hovenkamp, supra note 12, at 502; Hungar, supranote 12, at 532-33.
110. See Hovenkamp, supranote 12, at 503.
111. See Static Control Components, Inc. v. Lexmark Int'l, Inc., 615 F. Supp. 2d 575,
585-86 (E.D. Ky. 2009) (finding that Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617
(2008) overruled Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700 (Fed. Cir. 1992)).
112. See TransCore, LP v. Elec. Transaction Consultants Corp., 563 F.3d 1271, 1274 (Fed.
Cir. 2009).
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3
form, not substance-both are properly viewed as "'authorizations.""'l
The principal question, according to the court, was what the agreement
authorizes.
The patent exhaustion doctrine developed as a means to promote
efficiency in economic transactions and prevent the patent owner from
imposing unreasonable restraints on trade in an effort to derive a profit
in excess of what his invention warrants."' As Part III illustrates, the
patent exhaustion doctrine is complicated when the patented good can
self-replicate.

III. SELF-REPLICATING TECHNOLOGIES

Self-replication can be defined as any process by which a thing will
make a copy of itself.1 6 Because an article with self-replicating abilities
can potentially produce an unlimited number of copies once developed
one single patented article can have enormous commercial value"i
Although Moore v. Regents of the University of California" dealt with
the issue of property rights to one's own body parts, it demonstrates that
a cell line can be developed and used to treat an unlimited number of
patients." 9 In Moore, a cell line was developed from a 0patient's cells
and was patented in 1984 as U.S. Patent No. 4,438,032.12 The potential
market value of the patented cell line was estimated to be $3.01 billion
by 1990.121 The cell line provided a continuous source for a wide
variety of useful proteins.122 "[D]ue to the constitutive production of the
proteins, the cells provide either directly or indirectly, a source of the
genes for the proteins of interest, which by conventional genetic
engineering techniques, can be introduced into microorganisms for
continuous large scale production of the proteins."1 2 3
Self-replication is not unique to genetically modified seeds. The
biotechnology industry is replete with examples of self-replicating
technologies, including novel DNA sequences, virus strains,
113.
114.
115.
(1917).
116.

Id. at 1276.
Id.
See Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U.S. 502, 516
MERRIAM WEBSTER'S COLLEGIATE DICTIONARY 1062 (10th ed. 1994).

117. See, e.g., Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 482 (Cal. 1990).
118. 793 P.2d 479 (Cal. 1990).
119. Id at 494-95.
120. Id. at 482.
121. Id.
122. U.S. Patent No. 4,438,032 col.2 1.45-68 (filed Jan. 6, 1983) (invented by David W.
Golde & Shirley G. Quan, titled Unique T-lymphocyte Line and Products Derived Therefrom).
123. Id. col.2 1.63-68.
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microorganisms, cell lines, and bacteria.124 The potential use of selfreplicating technologies also includes the field of engineering, such as
material fabrication and nanostructure preparation.12 5 At the same time,
"not all self-replicating technologies are identical." 26 The process of
self-replication is different for different technologies.
Seeds are a flowering plant's unit of reproduction, capable of
developing into another plant of the same type. 27 Monsanto developed
genetically modified plants and seeds that are resistant to glyphosate
herbicides. 128 The advantage to Monsanto's seed technology is that the
herbicide can be sprayed broadly in planted fields, killing the weeds but
not harming the herbicide-resistant crops.129 Monsanto's patented seeds
by their nature self-replicate, as a seed's genetic traits carry forward into
each successive seed generation.' 30 Thus, the second-generation seeds
maintain the resistance to glyphosate.131
DNA sequences can be replicated. Polymerase chain reaction (PCR)
enables genetic material to be amplified in quantity both quickly and
reliably. 2 The use of PCR is common in all aspects of life sciences,
including "the detection of hereditary diseases, the identification of
genetic fingerprints, the diagnosis of infectious diseases, the cloning of
genes, paternity testing, and DNA computing." 33 New methods, such as
real-time PCR, are able to quantify genetic material in a single step. 34
PCR allows a target DNA sequence to be selectively amplified several
million-fold in just a few hours.135
DNA sequence can also be replicated in other ways. For example, a
124. See Brief of Amicus Curiae Law Professor Christopher M. Holman in Support of
Respondents at 10, Bowman v. Monsanto Co., 133 S. Ct. 1761 (2013) (No. 11-796) [hereinafter
Brief of Amicus Curiae Holman].
125. Mirjam E. Leunissen et al., Towards Self-Replicating Materials of DNAFunctionalizedColloids, 5 SOFT MATTER 2422, 2422 (2009).
126. Sheff, supra note 60, at 232.
127.

MERRIAM WEBSTER'S COLLEGIATE DICTIONARY 1057 (10th ed. 1994).

128. See Monsanto Co. v. Bowman, 657 F.3d 1341, 1343 (Fed. Cir. 2011).
129. Id. at 1344.
130. Id. at 1345.
131. Id.
132. See U.S. Patent No. 4,683,202 col.10 1.15-19 (filed Oct. 25, 1985) (invented by Kary
B. Mullis, titled Process for Amplifying Nucleic Acid Sequences).
133. U.S. Patent No. 7,955,802 col.1 1.22-26 (filed Dec. 13, 2007) (invented by Douglas
F. Whitman & Charles J. Collins, titled Systems and Methods for Multiplex Analysis of PCR in
Real Time).
134. See U.S. Patent No. 6,171,785 (filed June 6, 1995) (invented by Russell G. Higuchi,
titled Methods and Devices for Hemogeneous Nucleic Acid Amplification and Detector)
(proposing a single step method for PCR); see generally U.S. Patent No. 5,994,056 (filed May
2, 1991) (invented by Russell G. Higuchi, titled Homogeneous Methods for Nucleic Acid
Amplification and Detection).
135.

See STEPHEN L. WOLFE, MOLECULAR AND CELLULAR BIOLOGY 139 (1993).
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DNA molecule containing a particular gene can be introduced into E.
coli, a bacterium, "that serves as a factory to replicate many copies of
the DNA molecule and its gene. When an E. coli cell replicates by cell
division, the DNA in that E. coli cell also replicates, providing an
increased number of gene sequences from which protein can be

expressed."

36

Cell lines self-replicate by cell culture, which is capable of an
unlimited number of population doublings.13 7 Cell division and
duplication occur via a process called binary fission, during which a cell
grows, accumulating nutrients for duplicating its DNA, and splits itself
into two distinct cells. 38 Cell lines can be engineered for use in
therapeutic treatment. 139
"Genomic science has greatly enhanced our understanding of the
biological world. It is enabling researchers to 'read' the genetic code of
organisms . . . by sequencing the four letters that make up DNA."l 40

Essentially, "scientists are digitizing biology by converting the A, C, T,
and G's . . . of DNA into l's and 0's in a computer."' 4 By applying
advanced methodologies for engineering and synthesizing novel DNA
sequences, biologists are able to not only read the genetic code, but they
can create synthetic organisms. 14 2 In 2010, the first self-replicating
synthetic bacterial cell was created using genomic science. 143 With the
ability to "write the software of life," new products can be created and
used in fields, including "advanced biofuels, clean water technology,
and new vaccines and medicines." 44 Further, it is expected that
synthetic biology will produce many self-replicating products.14 5
With the sophistication of biological systems, information bearing
nanoscale patterns functionalized with DNA have the potential of
building self-replicating structures.146 The replication process takes
advantage of "the complementarity of the four-letter code of bases in
136. Invitrogen Corp. v. Biocrest Mfg. L.P., 327 F.3d 1364, 1366 (Fed. Cir. 2003).
137. See WOLFE, supra note 135, at 121.
138. Id. at 910-16.
139. See C.B. Newgard et a]., Engineered Cell Linesfor Insulin Replacement in Diabetes:
CurrentStatus and FutureProspects,40 DIABETOLOGIA 125, S42-43 (Supp. 1997).
140. First Self-Replicating Synthetic Bacterial Cell, J. CRAIG VENTER INST.,
http://www.jcvi.org/cms/research/projects/first-self-replicating-synthetic-bacterial-cell/overvie
w/?chocaid=397 (last visited Oct. 10, 2013) [hereinafter FirstSynthetic Cell].
14 1. Id.
142. Id
143. See Daniel G. Gibson et al., Creationof a BacterialCell Controlled by a Chemically
Synthesized Genome, 329 SCIENCE 52, 52 (2010).
144. FirstSynthetic Cell, supra note 140.
145. See Brief of Amicus Curiae Holman, supra note 124.
146. See Tong Wang et al., Self-Replication of Information-Bearing Nanoscale Patterns,
478 NATURE 225,225-28 (2011); Leunissen et al., supra note 125.
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the [] DNA double helix." 4 7 When temperature is raised and then
lowered, a DNA functionalized seed structure can melt into seed chains,
with the daughter chain assembling along the substructure, and link
together, forming a copy of the original structure due to the high
specificity. 4 8
The autonomous self-replication of a reconfigurable string from
randomly positioned input components has been realized.14 Input
components "could constitute self-fabricating systems" because the
parts assemble themselves. 50 Part of the system includes the ability for
the input components to "be reversibly latched and unlatched in
response to nearest-neighbour communications."' 5'
In another example, a set of modular robot cubes can selfreplicate.152 The robots' "modules have electromagnets that selectively
weaken and strengthen connections, determining where the structure
breaks and joins." 53 The robots also contain a microcontroller that
"executes a motion schedule governed by time and contact events" that
enables them to form into an arbitrary arrangement.1 54 With materials
supplied, the robot constructed a replica of itself in minutes "by lifting
and assembling cubes."15 5
Self-replicating technologies involve more than the seed industry.
The amount of human intervention can vary greatly for different
technologies. For example, seeds can be dropped incidentally during
transportation and grow by themselves, but a self-replication of a
modular robot probably needs much more preparation, including
supplying the parts and providing the facility. Under certain
circumstances, instead of creating exact replications of the patented
articles, modified copies of the articles can be produced.156 For
example, mistakes during DNA replication result in mutations, "which
constitute any difference in sequence from the parental template that
appears . . . in the replicated copies." 5 7 Besides errors inherent in the
DNA replication, mutations can also be induced by external exposure,

147.
148.
I49.
636, 636
150.
151.
152.
(2005).
153.
154.
155.
156.
157.

Wang et al., supra note 146, at 225.
See Leunissen et al., supra note 125, at 2428-29.
See Saul Griffith et al., Robotics: Self-Replication from Random Parts, 437 NATURE
(2005).
Id.
Id.
Victor Zykov et al., Robotics: Self-Reproducing Machines, 435 NATURE 163, 163
Id.
Id.
Id.
See WOLFE supra note 135, at 121.
Id. at 952.
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such as ultraviolet radiation.' 5 8
In terms of the ease to replicate, the biotechnology industry is
probably similar to the seed industry, as both are capable of creating an
unlimited number of replications with a small amount of resources. The
determination of how patent exhaustion applies to Monsanto's Roundup
Ready seeds may have the greatest impact on the biotechnology
industry in the near future.
IV. PATENT EXHAUSTION AND SELF-REPLICATING
TECHNOLOGIES AT THE FEDERAL CIRCUIT

Although Bowman v. Monsanto marks the first time the Supreme
Court decided a patent exhaustion case involving self-replicating
technology, the Federal Circuit has dealt with the issue in several cases,
all of which involved Monsanto's transgenic seeds.159 In each of these
cases, the Federal Circuit declined to apply patent exhaustion to the
seeds after initial sale on the grounds of the conditional sale doctrine
and the making of new infringing articles.' 60
Monsanto develops, manufactures, licenses, and sells agricultural
biotechnology and agricultural chemicals.'61 One of the most popular
product classes that Monsanto developed is the Roundup family of
glyphosate herbicides, 162 which is highly effective in eliminating weeds,
158. See U.S. Patent No. 2003/0105027 (filed Apr. 25, 2002) (invented by Richard A.
Rosenbloom, titled Nutritional Supplements and Methods for Prevention, Reduction and
Treatment of Radiation Injury).
159. See, e.g., Monsanto Co. v. McFarling, 302 F.3d 1291 (Fed. Cir. 2002); Monsanto Co.
v. Scruggs, 459 F.3d 1328 (Fed. Cir. 2006); Monsanto Co. v. Bowman, 657 F.3d 1341 (Fed. Cir.
2011).
160. See McFarling,302 F.3d at 1298-99; Scruggs, 459 F.3d at 1335-36; Monsanto, 657
F.3d at 1347-48.
161. See Brief for Respondents at 2, Bowman v. Monsanto Co., 133 S. Ct. 1761 (2013)
(No. 11-796).
162. See e.g., U.S. Patent No. RE39,247 E (filed July 18, 2003) (invented by Gerard F.
Barry et al., titled Glyphosate-Tolerant 5-Enolpyruvylshikimate-3-Phosphate Synthases); U.S.
Patent No. 5,633,435 (filed Sept. 13, 1994) (invented by Gerard F. Barry et al., titled
Glyphosate-Tolerant 5-Enolpyruvyshikimate-3-Phosphate Synthases); U.S. Patent No.
5,352,605 (filed Oct. 28, 1993) (invented by Robert T. Fraley et al., titled Chimeric Genes for
Transforming Plant Cells Using Viral Promoters); U.S. Patent No. 5,322,938 (filed Nov. 17,
1992) (invented by Joan C. McPherson & Robert Kay, titled DNA Sequence for Enhancing the
Efficiency of Transcription); U.S. Patent No. 5,196,525 (filed Apr. 8, 1991) (invented by Joan
C. McPherson & Robert Kay, titled DNA Construct for Enhancing the Efficiency of
Transcription); U.S. Patent No. 5,164,316 (filed Aug. 17, 1989) (invented by Joan C.
McPherson & Robert Kay, titled DNA Construct for Enhancing the Efficiency of
Transcription); U.S. Patent No. 3,977,860 (filed June 11, 1973) (invented by John E. Franz,
titled Herbicidal Compositions and Methods Employing Esters of N-Phosphonomethylglycine);
U.S. Patent No. 3,799,758 (filed Aug. 9, 1971) (invented by John E. Franz, titled N-
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but also damages other plants, including crops not resistant to the
herbicide. 163 Monsanto developed genetically modified plants and seeds
that are resistant to glyphosate herbicides.1 64
"Since 1996, Monsanto has marketed and sold Roundup Ready
soybean seeds under its own brands, and licenses its technology to seed
producers who insert the Roundup Ready genetic trait into their own
seed varieties."l 65 Every farmer who wants to buy Roundup Ready
seeds must execute a Technology Agreement, obtain a limited-use
license to Monsanto's patents, and pay a price that includes a passthrough of Monsanto's royalty.' 66 Under the Technology Agreement,
among other restrictions, "the seeds are to be used for 'planting a
commercial crop only in a single season"' and the farmers cannot "'save
any crop produced from this seed for replanting, or supply saved seeds
to anyone for replanting."' Monsanto explained that these restrictions
on the use of subsequent generations of the seed for planting are
necessary because Roundup Ready technology is self-replicating.16 8
Some crops, like soybeans, present a particular concern for Monsanto
because they self-replicate at an exponential rate, and the harvested
commodity is essentially identical to the planted seed.1 69
In Monsanto Co. v. Bowman, Bowman, a farmer, purchased
Roundup Ready seed from a licensed seed producer beginning as early
as 1999, executed a Technology Agreement, and, consistent with the
terms of the Technology Agreement, did not save seed from his firstcrop during the years 1999 through 2007.170 However, for Bowman's
second-crop of 1999, he "also purchased commodity seed from a local
grain elevator" in an effort "to avoid paying the significantly higher"
seed price, knowing that many of the plants were resistant to
glyphosate-based herbicide. 7' In determining whether Bowman's use
Phosphonomethyl-Glycine Phototoxicant Compositions).
163. See Brief for Respondents, supra note 161, at 1.
164. See Monsanto, 657 F.3d at 1343.
165. Id. at 1344.
166. Id. at 1344-45; see also Monsanto Co. v. Scruggs, 459 F.3d 1328, 1333 (Fed. Cir.
2006); Monsanto Co. v. McFarling, 302 F.3d 1291, 1293 (Fed. Cir. 2002).
167. McFarling,302 F.3d at 1293; Monsanto, 657 F.3d at 1344-45.
168. See Brief for Respondents, supra note 161, at 4.
169. Id.
170. See Monsanto, 657 F.3d at 1345. The Technology Agreement "authorizes growers to
sell second-generation seed to local grain elevators as a commodity." Id. The seeds that are
initially bought by the farmers from Monsanto or licensed seed producers are considered firstgeneration seeds. See id. at 1344-45. The seeds produced by the plants grown from the firstgeneration seeds are second-generation seeds. See id. at 1345.
171. Id. "Unlike his first-crop, Bowman saved the seed harvested from his second-crop for
replanting additional second-crops in later years." Id. at 1346. Additionally, Bowman
"supplemented his second-crop planting supply with periodic additional purchases of
commodity seed from the grain elevator." Id.
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of the seeds purchased from the grain elevator infringed Monsanto's
patents, the Federal Circuit held that patent exhaustion does not apply
because Bowman was making "newly infrining" seeds.172
In both Monsanto Co. v. McFarling and Monsanto Co. v.
Scruggs,174 the Federal Circuit also dealt with the unauthorized planting
of second-generation seeds.' 7 5 In McFarling,a farmer violated the terms
of his Technology Agreement by saving Roundup Ready soybeans from
one growing season and replanting those seeds in the next season. 176
The Federal Circuit found that patent exhaustion did not apply because
there was no authorized sale-the conditions in Monsanto's Technology
Agreement were within the scope of its patent rights and thus valid, and
the new seeds grown from the original batch had never been sold by
Monsanto.1 77 In Scruggs, Scruggs purchased Roundup Ready soybean
seeds from one of Monsanto's authorized seed companies but never
signed the Technology Agreement.' 7 8 Scruggs planted the purchased
seeds, harvested them, and replanted the second-generation seeds
containing the Roundup Ready trait. 179 The Federal Circuit again held
that the patent exhaustion doctrine did not apply, and accordingly,
"[t]here was no unrestricted sale because the use of the seeds by seed
growers was conditioned on obtaining a license from Monsanto."' 8 0
Moreover, the Federal Circuit found that "the "first sale' doctrine of
exhaustion of the patent right is not implicated as the new seeds grown
from the original batch had never been sold.'

V.

BOWMAN V. MONSANTO: THE SUPREME COURT CASE INVOLVING
SELF-REPLICATING TECHNOLOGY

The Supreme Court affirmed the Federal Circuit's decision in
Bowman v. Monsanto.182 A unanimous Supreme Court found that
planting patented seeds and harvesting more seeds fell outside the
doctrine of patent exhaustion, which does not allow a farmer to
reproduce patented seeds without the patent holder's permission.' 8 3 As a
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.

Id. at 1347-48.
302 F.3d 1291 (Fed. Cir. 2002).
459 F.3d 1328 (Fed. Cir. 2006).
See McFarling,302 F.3d at 1293; Scruggs, 459 F.3d at 1333.
See McFarling,302 F.3d at 1293.
Id. at 1298-99.
See Scruggs, 459 F.3d at 1333.
Id.
Id. at 1336.
Id. (quoting McFarling,302 F.3d at 1299).
133 S. Ct. 1761, 1769 (2013).
Id.
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result, Bowman infringed on Monsanto's patents when he planted
genetically-modified soybean seeds not purchased from the company.184
Among other reasons, the Court based its decision on both law and
policy: (1) patent exhaustion does not extend to the right to make a new
product- and (2) allowing copying would reduce the value of the
patent. A
A. Patent ExhaustionDoes Not Extend to the Right to Make a
New Product
According to the Court, the patent exhaustion doctrine "restricts a
patentee's rights only as to the 'particular article' sold."' 8 6 The doctrine
"does not enable Bowman to make additional patented soybeans
without Monsanto's permission," which can be express or implied.' 8 7
Bowman took the soybeans he purchased home, planted them, applied
glyphosate to kill the weeds, and harvested more seeds, thereby making
new products.' 8 8 Because Bowman "reproduced Monsanto's patented
invention," the Court ruled that "the exhaustion doctrine does not
protect him."' 8 9 The Court also noted that it does not matter whether
Bowman purchased the seed from a Monsanto-affiliated seed company
or from the grain elevator.19 0
The decision in Bowman v. Monsanto is consistent with the Court's
finding in other patent exhaustion cases: from Adams to Quanta-patent
exhaustion was limited only to the specific item that was sold.'9' The
Court also applied similar logic in Microsoft Corp. v. AT&T Corp.,192
where identical copies of software were treated as separate components
from the master disk used to make them, even though the only use of
the master disk was to create such copies.' 93 There, the Court indicated
that making copies of software is like making copies of biological
material through reproduction by stating that "[c]opying software
abroad, all might agree, is indeed easy and inexpensive. But the same
could be said of other items [such as]: .. .'chemical or biological

184. Id at 1766-67.
185. Id. at 1766-68.
186. Id. at 1766 (quoting United States v. Univis Lens Co., 316 U.S. 241, 251 (1942)).
187. Id.
188. Id at 1766-67.
189. Id. at 1767.
190. Id. n.3.
191. See Adams v. Burke, 84 U.S. 453, 456 (1873); Quanta Computer, Inc. v. LG Elecs.,
Inc., 553 U.S. 617, 625 (2008) ("The longstanding doctrine of patent exhaustion provides that
the initial authorized sale of a patented item terminates all patent rights to that item.").
192. 550 U.S. 437 (2007).
193. Id. at 451-52.
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substances [that] might be created by reproduction . . . ."'l94
In addition, Bowman v. Monsanto is consistent with Supreme
Court's precedent concerning repair and reconstruction.' 95 It is well
established that one who owns a patented article may repair it, but not
reconstruct it.196 In Aro Manufacturing Co. v. Convertible Top
Replacement Co.,197 it was permissible to repair the worn fabric on the
patented convertible automobile based on the purchaser's right to
maintain the patented article for its intended use.1 9 In Cotton-Tie Co. v.
Simmons,199 however, creating new cotton ties "by piecing together
severed pieces of' old patented ties was impermissible reconstruction
and constituted an infringement.2 00 A "true reconstruction" that results
in the making of "a new article" constitutes patent infringement. 201
Thus, a prohibited reconstruction occurs when "a new article" is made
after the patented article, when "viewed as a whole, has become
spent."20 2 Thus, "Mr. Bowman's replanting of commodity seed was no
mere 'repair' of the patented article . . . [because] the original seed sold

by Monsanto had performed its use and had been consumed in the very
first planting." 203
B. Allowing Copying Would Reduce the Value of the Patent
In Bowman v. Monsanto, the Court's reasoning was further
motivated by maintaining incentives to invent new and useful
technologies. 4 The Court explained that exhausting a patent after only
one generation of growing a crop from genetically engineered seeds
would effectively undermine the entire patent concept, and reduce the
patent monopoly from twenty years to less than one.20 5 The Court
provided that, "If the purchaser of [the] article could make and sell
194. Id. at 453-54 (quoting Brief for the United States as Amicus Curiae at 24, Bowman v.
Monsanto Co., 133 S. Ct. 1761 (2013) (No. 11-796)).
195. See, e.g., Brief for the United States as Amicus Curiae at 14, Bowman v. Monsanto
Co., 133 S. Ct. 1761 (2013) (No. 11-796); Brief of BSA the Software Alliance as Amicus
Curiae in Support of Respondents at 12, Bowman v. Monsanto Co., 133 S. Ct. 1761 (2013) (No.
11-796) [hereinafter Brief of BSAJ.
196. See Aro Mfg. Co. v. Convertible Top Replacement Co., 365 U.S. 336, 346 (1961);
Jazz Photo Corp. v. Int'l Trade Comm'n, 264 F.3d 1094, 1104-05 (Fed. Cir. 2001).
197. 365 U.S. 336 (1961).
198. See id. at 337-40, 346.
199. 106 U.S. 89 (1882).
200. See id. at 93-95.
201. See Aro Mfg. Co., 365 U.S. at 346.
202. Id.
203. Brief of Intellectual Property Owners Association as Amicus Curiae in Support of
Respondents at 5, Bowman v. Monsanto Co., 133 S. Ct. 1761 (2013) (No. 11-796).
204. See Monsanto, 133 S. Ct. at 1768.
205. Id.

2013]1

SELF-REPLICA TING TECHNOLOGIES: DO THEY EXHAUST PA TENT RIGHTS?

221

endless copies, the patent would effectively protect the invention for
just a single sale." 20 In addition, the Court found that the benefit of the
patent would be insufficient because "other seed companies could
reproduce the product and market it to growers, thus depriving
Monsanto of its monopoly." 207 Farmers need to only buy the seed once
to multiply it, profiting from the patented seed without paying its patent
owner.2 Had the Court decided otherwise, there would be a mismatch
between invention and reward and the patent would afford little
protection to the inventor.20 9
The Court's analysis could have been influenced by the severe
consequences for Monsanto and others like it. According to Monsanto,
"[b]y authorizing use of its technology for a single growing season in
exchange for a small royalty, Monsanto can incrementally recover its
research and development investment through multiple transactions
over many years, making use of the invention affordable." 2 10 Monsanto
spent "hundreds of millions of dollars and more than a decade" to
develop the Roundup Ready technology.211 Monsanto's position was
supported by other groups across a range of industries that worried that
a ruling against the company could undermine their research efforts. 2 12
The briefs of Monsanto and its amici, such as the Biotechnology

Industry Organization, had emphasized the high up-front costs of
developing genetically engineered products like the Roundup Ready
seed.21 For example, in 2010, biotechnology companies "spent $22.8
billion on research and development." 2 14 Further, like seeds, cells can
self-replicate, and it may take only a handful of seeds or a single cell
line to completel eviscerate the patent owner's rights if patent
exhaustion applies.
206. Id at 1766.
207. Id at 1767.
208. Id.
209. Id.
210. Brief for Respondents, supranote 161, at 13.
211. Id at 2.
212. See, e.g., Brief of Economists as Amici Curiae in Support of Respondents, Bowman
v. Monsanto, 133 S. Ct. 1761 (2013) (No. 11-796), 2013 WL 267023; Brief of the American
Seed Trade Association as Amicus Curiae in Support of Respondents, Bowman v. Monsanto,
133 S. Ct. 1761 (2013) (No. 11-796), 2013 WL 267021; Brief of Washington Legal Foundation
as Amicus Curiae in Support of Respondents, Bowman v. Monsanto, 133 S. Ct. 1761 (2013)
(No. 11-796), 2013 WL 267022; Brief for the American Intellectual Property Law Association
as Amicus Curiae in Support of Affirmance, Bowman v. Monsanto 133 S. Ct. 1761 (2013) (No.
11-796), 2013 WL 314458.
213. See Brief of the Biotechnology Industry Organization as Amicus Curiae in Support of
Respondents, Bowman v. Monsanto, 133 S. Ct. 1761 (2013) (No. 11-796) [hereinafter Brief of
BIO].
214. Id. at 7.
215. Id. at 35.
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C. Bowman's Other Arguments
In response to Bowman's argument that he had used the seeds
precisely as they were intended to be used-to plant them-the Court
stated that accepting that theory would create an "unprecedented
exception" to the exhaustion doctrine. 2 16 "[I]f simple copying were a
protected use," the Court elaborated, "a patent would plummet in value
after the first sale of the first item containing the invention. 2 1 7
Additionally, Bowman argued that he did not create the new seeds,
rather "it was the planted soybean" because "soybeans naturally 'selfreplicate or 'sprout' unless stored in a controlled manner."' 218 However,
the Court rejected this "blame-the-bean defense." 2 19 The Court reasoned
that "Bowman was not a passive observer of his soybeans'
multiplication; . . . the seeds he purchased (miraculous though they

might be in other respects) did not spontaneously create eight
successive soybean crops.

. .

. [I]t was Bowman, and not the bean, who

controlled the reproduction (unto the eighth generation) of Monsanto's
patented invention."220
VI. POTENTIAL IMPACT OF THE BOWMAN DECISION AND
ISSUES NOT DECIDED

A. PotentialImpact of the Bowman Decision
The Court's decision in Bowman v. Monsanto indicates that
inventions involving replicating technologies can be adequately
protected under the patent laws, which is critical to the agriculture and
the biotechnology industry. Bowman v. Monsanto was expected to have
far-reaching implications for other self-replicating technologies, but the
Court explicitly refrained from such a broad ruling. 221 The Court limited
its holding to the specific facts of the case, "rather than every one
involving a self-replicating product." 222 The Court's limited holding
appears to be because "inventions are becoming ever more prevalent,
complex, and diverse. In another case, the article's self-replication
might occur outside the purchaser's control. Or it might be a necessary

216.
217.
218.
Ct. 1761
219.
220,
221.
222.

Bowman v. Monsanto Co., 133 S. Ct. 1761, 1768 (2013).
Id.
Id. at 1768-69 (quoting Brief for Petitioner at 42, Bowman v. Monsanto Co., 133 S.
(2013) (No. 11-796)).
Id. at 1769.
Id.
Id.
Id.
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but incidental step in using the item for another purpose." 223
The Court's decision was welcomed by the biotechnology
industry. 224 The Biotechnology Industry Organization issued a
statement supporting the ruling because it confirmed "the legitimacy of
the long-established patent licensing practices" in biotechnology and
"create[d] business certainty that will benefit all of biotechnology." 225
However, people in the biotech-pharmaceutical industry should not
get too carried away because the Court explicitly limited the ruling to
the facts of the case. 2 6 In addition, although the reproduction of seeds is
similar to the reproduction of many products in biotechnology in terms
of the ease to replicate, biotechnology is much more complex. For
example, specific and intentional changes can be made to the DNA
sequence of a gene during reproduction. 2 When any change in a DNA
molecule alters its sequence, it no longer represents an exact copy of its
parental DNA molecule; instead, it constitutes a mutation.2 28 In a widely
used method, mutations can be easily2 enerated, and cloned DNAs with
modified sequences can be produced. Therefore, in the biotechnology
world, human activity can induce small changes to the original DNA
sequence or cell lines, which is distinguishable from Bowman v.
Monsanto where the second-generation seeds are identical copies of the
original seeds.2 30
Although the Court intended for the Bowman v. Monsanto decision
to be limited to the facts of the case, several factors mentioned in the
case may be important to consider in future cases.2 3' One factor is
223. Id.
224. See Press Release, Jeff Greenwood, President & Chief Exec. Officer, Biotechnology
Indus. Org., BIO Commends Supreme Court's Support for Continued Biotech Innovation (May
14,
2013),
http://www.bio.org/medialpress-release/bio-commends-supreme-courts-supportcontinued-biotech-innovation.
225. Id.; see also Dale Hildebrant, U.S. Supreme Court Rules in Favor of Monsanto on
Seed Patent Issues, FARM & RANCH GUIDE (June 4, 2013, 1:36 PM), http://www.farmandranch
guide.com/news/crop/us-supreme-court-rules-in-favor-of-monsanto-on-seed/article_b2dc41a6cd45-1 l e2-9d71-0019bb2963f4.html.
226. See Monsanto, 133 S. Ct. at 1769.
227. See, e.g., '202 Patent, supra note 132, at 12-13 (explaining that the process of
polymerase chain reaction can be used in different ways to mutate a DNA sequence); Invitrogen
Corp. v. Biocrest Mfg. L.P., 327 F.3d 1364, 1366 (Fed. Cir. 2003) (stating that E. coli can be
used to intentionally replicate a DNA molecule); Brief for Respondents, supra note 161, at 10
(arguing that scientists can use specific methods to create synthetic organisms that selfreplicate).
228. See WOLFE, supra note 135, at 983.
229. Oded Edelheit et al., Simple and Efficient Site-Directed Mutagenesis Using Two
Single-Primer Reactions in Parallel to Generate Mutants for Protein Structure-Function
Studies, BMC BIOTECHNOLOGY, June 2009, at 1.

230. See Monsanto, 133 S. Ct at 1765.
231. Id. at 1764-65, 1769.

JOURNAL OF TECHNOLOGYLAW&

224

POLICY

[Vol. I18

whether the self-replication occurs outside of the purchaser's control.232
In Bowman v. Monsanto, Bowman was not a passive observer; rather,
he planted and harvested the seeds.2 33 If the patented article
spontaneously replicates itself, it may favor applying the exhaustion
doctrine.234 Another factor is whether there is a substantial noninfringing use.235 Seeds have non-infringing uses, such as reselling the

patented soybeans that Bowman bought from the grain elevator,
consuming the soybeans himself, or using the soybeans as animal
food.2 36 As in Bowman v. Monsanto, the Court will look at the impact
on the incentive to invent.237 Other factors ma include the importance
of downstream use and the ease of replication.2 8
As self-replicating technologies become more mature in society,
more cases involving these technologies will likely be brought, which
will provide the courts with opportunities to clarify the scope of the
holding in Bowman v. Monsanto.
B. InadvertentInfringement and Self-Replicating Technologies
Because patent exhaustion does not apply to patented seeds, there
may be a concern about inadvertent infringement, such as when seeds
are blown onto a farmer's land by wind.2 Farmers that grow organic
products do not even want Roundup Ready seeds growing on their
farm.240 In Organic Seed Growers and Trade Association v. Monsanto
Co.,241 a case involving Monsanto's seeds, a group of more than fifty
organizations sought declaratory judgments that would prohibit
Monsanto from suing the farmers or seed dealers if their organic seed
became contaminated with Monsanto's patented biotech seed.24 2
232. Id. at 1765, 1769.
233. Id. at 1769.
234. Id. at 1766 (holding that "the exhaustion doctrine does not extend to the right to
'make' a new product" (quoting Brief for Petitioner at 37, Bowman v. Monsanto Co., 133 S. Ct.
1761 (2013) (No. 11-796)).
235.

Id.

236. Id.
237. See id. at 1768.
238. Id. at 1768-69; see also Eric J. Rogers, The Inexhaustible Right to Exclude
Reproduction Doctrine, 14 COLUM. Sa. & TECH. L. REv. 389, 480-81 (2013).
239. See Organic Seed Growers & Trade Ass'n v. Monsanto Co., 718 F.3d 1350, 1356-57
(Fed. Cir. 2013).
240. See Organic Seed Growers & Trade Ass'n v. Monsanto Co., 851 F. Supp. 2d 544, 548
(S.D.N.Y. 2012). The plaintiffs in Organic Seed Growers and Trade Association v. Monsanto
Co. constituted farmers, seed businesses, and other related organizations, all of whom were
opposed to "use[ing], grow[ing] crops raised from, or sell[ing] transgenic seed, which is seed
that has had genetic code of another species introduced to it." Id.
241. 851 F. Supp. 2d 544 (S.D.N.Y. 2012).
242. Id. at 549.
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response, Monsanto maintained that it was committed to not suing
farmers over the inadvertent presence of trace amounts of patented
seeds or traits in their fields.2 43 The U.S. District Court for the Southern
District of New York found that there was no likelihood that Monsanto
would pursue patent infringement cases against the organic farmers that
had no interest in using the company's patented seed products. 244 Te
Federal Circuit affirmed the district court, holding that the plaintiffs
"have not alleged any circumstances placing them beyond the scope of'
Monsanto's assurances.245
Therefore, although the court did not discuss whether inadvertent
replication of the patented article would infringe the patent, it seems
that inadvertent infringement will not be an issue in the situation
involving Monsanto's seed.
C. Authorized Sale and Self-Replicating Technologies
Previous patent exhaustion cases often focused on whether there was
an authorized sale. In Bowman v. Monsanto, however, the Court did not
discuss whether the sale of the first-generation seed to Bowman was an
authorized sale. 246 Instead, the decision was based on whether the
second-generation seed fell outside of the patent exhaustion doctrine. 24 7
Because the Court expressly limited its decision, second-generation
articles of other self-replicating technologies may still fall under the
doctrine of patent exhaustion.2 4 8 If that happens, it will become
important to determine whether the sale of the first-generation product
constitutes an authorized sale. The following analysis indicates that the
sale of the seed to Bowman was authorized.
In Quanta, although Intel was required to provide notice to
purchasers to combine them with only Intel parts, the Court applied the
patent exhaustion doctrine partially because neither Farty contended that
Intel breached the agreement in that respect.2 Like in Quanta,
although the original Technology Agreement prohibits selling the seeds
for replanting, Monsanto does not allege patent infringement either
from the seed producer or the grain elevator. 2 50 Although Monsanto
243. Id. at 550.
244. Id. at 553. The court dismissed the case because the plaintiffs failed to "show[] that
there is a substantial controversy, between parties having adverse legal interests, of sufficient
immediacy and reality to warrant the issuance of a declaratory judgment." Id. at 556.
245. Organic Seed Growers & Trade Ass'n v. Monsanto Co., 718 F.3d 1350, 1352, 1361
(Fed. Cir. 2013).
246. See Bowman v. Monsanto Co., 133 S. Ct. 1761, 1766-67 (2013).
247. Id.
248. Id. at 1769.
249. Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617, 636 (2008).
250. See id.; Monsanto, 133 S. Ct. at 1764-65.
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required the seed producer to execute the Technology Agreement with
every purchaser regarding the permissible use of its patented seeds, 2 5 1 if
Monsanto never intended to sue the seed producer, it is similar to the
unconditional covenant not to sue described in TransCore, LP v.
Electronic Transaction Consultants Corp.252 In TransCore,the Federal
Circuit held that "an unconditional covenant not to sue authorizes sales
by the covenantee for purposes of patent exhaustion." 253 Therefore, the
sales are authorized.
In addition, the Court in Quanta held that "[t]he authorized sale of
an article that substantially embodies a patent exhausts the patent
holder's rights and prevents the patent holder from invoking patent law
to control post-sale use of the article." 254 The patented seed always
"substantially embodies" the patent.255 Because a product containing
patented genetic material completely embodies the patent, it follows
that the use of Monsanto's seed practices embody the Monsanto patents,
despite whether the seeds are being planted or fed to livestock.25 "Even
more so than the incomplete computer parts in Quanta, progeny seeds"
exhibit the genetic trait for glyphosate resistance, thereby embodying
the patented qualities of their predecessor seed.25 7 Moreover, planting
seed is a "common" and "non-inventive" step that results in an item
"substantially embod[ying]" the patented product. 2 58 Therefore, as to
the first-generation seed, Monsanto's practice would constitute an
authorized sale.
CONCLUSION

The Supreme Court addressed patent exhaustion in the context of
self-replicating technology in Bowman v. Monsanto, finding that
making new copies falls outside the doctrine of patent exhaustion. 259
Although the Court emphasized that the decision is limited to the facts
of the case, the decision will likely have long-term implications for self251. See Monsanto Co. v. Bowman, 657 F.3d 1341, 1344 (Fed. Cir. 2011).
252. 563 F.3d 1271 (Fed. Cir. 2009).
253. Id. at 1274.
254. Quanta, 553 U.S. at 638.
255. Brief of Amici Curiae the American Antitrust Institute, National Farmers Union,
Food & Water Watch, Organization for Competitive Markets, and National Family Farm
Coalition in Support of Petitioner at 13, Bowman v. Monsanto Co., 133 S. Ct. 1761 (2013) (No.
11-796), 2012 WL 6208274 at *8.
256. See id.
257. Brief for Amici Curiae Center for Food Safety and Save Our Seeds in Support of
Petitioner at 30, Bowman v. Monsanto Co., 133 S. Ct. 1761 (2013) (No. 11-796).
258. See Quanta, 553 U.S. at 638.
259. See Bowman v. Monsanto Co., 133 S. Ct. 1761, 1766-67 (2013).
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replicating technologies.260 When other self-replicating technologies
become more developed, Bowman v. Monsanto will provide guidance as
to the factors the Court may consider in deciding whether the doctrine
of patent exhaustion applies. 2 61

260.
261.

Id. at 1769.
Id.
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